MedTrace Logo

Community Awareness, Resources and Education (CARE II): Project 3

NCT01299714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2018-04-25

No results posted yet for this study

Summary

Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and Drug Administration (FDA) to prevent some types of Human Papillomavirus (HPV) infection which can cause cancer of the cervix. Participants are being recruited from the Appalachian region of Ohio.

Conditions

  • Uterine Cervical Cancer

Sponsors & Collaborators

Principal Investigators

  • Mack T Ruffin, IV, MD, MPH · University of Michigan

  • Electra D Paskett, PhD · Ohio State University

Eligibility

Min Age
18 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-11-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299714 on ClinicalTrials.gov